Mechanism: Progranulin Loss and TDP-43 Pathology in FTD

V2, Crosslink

🧫

Mechanism: Progranulin Loss and TDP-43 Pathology in FTD

active

experiment Created: 2026-04-02T10:01:41 By: crosslink-v2 Quality: 67% ✓ SciDEX ID: experiment-exp-wiki-experiments-progranu

🧫 Experiment Protocol Validationproposed

SUMMARY

# Mechanism: Progranulin Loss and TDP-43 Pathology in FTD ## Background and Rationale Frontotemporal dementia (FTD) represents the second most common early-onset dementia, with heterozygous mutations in the progranulin gene (GRN) accounting for 5-25% of familial cases. GRN haploinsufficiency leads to reduced progranulin protein levels, triggering a pathogenic cascade culminating in abnormal TDP-43 protein aggregation and neuronal dysfunction. This validation study employs human post-mortem brain

METHODOLOGY NOTES

Phase 1: Post-mortem tissue analysis (Weeks 1-8). Collect frozen frontal/temporal cortex samples from GRN mutation carriers (n=20), sporadic FTD cases (n=20), and age-matched controls (n=15). Perform immunohistochemistry using anti-progranulin (1:500, R&D Systems) and phospho-TDP-43 antibodies (1:1000, CosmoBio). Quantify progranulin levels via sandwich ELISA and assess TDP-43 aggregation burden using stereological counting methods. Phase 2: iPSC neuronal modeling (Weeks 9-20). Culture patient-derived iPSCs from GRN carriers (n=8) and healthy controls (n=6). Differentiate to cortical neurons using dual SMAD inhibition protocol over 35 days. Treat with lysosomal stressors (chloroquine 10μM, bafilomycin 100nM) to accelerate pathology. Monitor TDP-43 subcellular localization via immunofluorescence microscopy at days 21, 35, and 49. Assess neuronal viability using MTT assays and measure progranulin secretion in conditioned media. Phase 3: CSF biomarker validation (Weeks 21-24). Analyze cer

▸Metadatasource: {'type': 'manual', 'source_name': 'wiki'

source	{'type': 'manual', 'source_name': 'wiki', 'extracted_by': 'backfill_v1', 'extraction_date': '2026-04-16T01:00:16.900227Z'}
summary	# Mechanism: Progranulin Loss and TDP-43 Pathology in FTD ## Background and Rationale Frontotemporal dementia (FTD) represents the second most common early-onset dementia, with heterozygous mutations
entities	{'genes': ['TDP'], 'diseases': ['ALS']}
model_system	human
_schema_version	1
experiment_type	validation
primary_outcome	Validate Mechanism: Progranulin Loss and TDP-43 Pathology in FTD
methodology_notes	Phase 1: Post-mortem tissue analysis (Weeks 1-8). Collect frozen frontal/temporal cortex samples from GRN mutation carriers (n=20), sporadic FTD cases (n=20), and age-matched controls (n=15). Perform
replication_status	single_study
extraction_metadata	{'backfill_at': '2026-04-16T01:00:16.900232', 'needs_review': True, 'extraction_notes': 'Backfilled from wiki source (no PMID available)', 'extraction_confidence': 0.4}

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

613

Outgoing

487

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Mechanism: Progranulin Loss and TDP-43 Pathology in FTD

derives from (16)

supports (33)

💬 Discussion